- Home
- Companies
- LightDeck Diagnostics
- Products
- Lightdeck - Host-Response Diagnostics
Lightdeck - Host-Response Diagnostics
We are developing point-of-care, multiplex tests for host-response biomarkers in blood.
Worldwide
Affects 30 million people, 6 million deaths annually.
*Source: Sepsis Alliance
Speed matters
Sepsis can progress rapidly and can be fatal. Each hour of delay in giving antibiotics increases risk of death by 7%.
*Source: Sepsis Alliance
High cost
Costs $27 billion annually in the U.S.
*Source: Sepsis Alliance
Host-response biomarkers are associated with inflammation and can be measured early in acute infection. Research indicates that certain combinations of these biomarkers may be prognostic for cytokine storm, which is an out-of-control immune response that is and associated with bad outcomes in COVID-19 and sepsis. Our panels will provide rapid results that may give insights about immune response, may help inform treatment decisions and may direct resource allocation in a crisis.
Information Provided
Differientiate
Differentiate between infectious vs. non-infectious etiology
Staging
Where the patient is on the disease continuum: low-risk to cytokine storm?
Monitoring
Assess response to treatment